ARRDC4 drives Tau pathology via USP14‐mediated deubiquitination and acts as a novel therapeutic target in Alzheimer's disease
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 29.10.2026. Verfasst von Jiaqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetics and Development of Complex Phenotypes, Department of Cell and Developmental Biology at School of Life Sciences, Inst…. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Ubiquitin Thiolesterase, Drosophila Proteins. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Hyperphosphorylated Tau accumulation drives neurodegeneration in Alzheimer's disease (AD), but mechanisms linking impaired Tau ubiquitination to disease progression remain incompletely defined. METHODS We integrated Drosophila RNAi screening, human AD datasets, cellular assays, and mouse tauopathy models to evaluate arrestin domain‐containing 4 (ARRDC4) in Tau pathology. ARRDC4‐dependent regulation of Tau ubiquitination was examined using proteomics, proximity labeling, co‐immunoprecipitation, BiFC, domain mapping, genetic suppression, and small‐molecule interference. RESULTS ARRDC4 was upregulated in AD‐relevant human and animal datasets and correlated with Tau burden. ARRDC4 overexpression promoted Tau phosphorylation, self‐association, seeded aggregation, secretion, and inflammatory activation. Mechanistically, ARRDC4 brought Tau and USP14 into proximity, suppressing Tau ubiquitination. Genetic ARRDC4 deficiency or pharmacological disruption of the ARRDC4–USP14 interface restored Tau ubiquitination and ameliorated Tau pathology, neuroinflammation, neuronal injury, and behavioral deficits across cellular, Drosophila , and mouse models. DISCUSSION ARRDC4 is a regulator of Tau proteostasis and a potential therapeutic target for Tau‐associated AD pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Genetics and Development of Complex Phenotypes, Department of Cell and Developmental Biology at School of Life Sciences, Institute of Metabolism and Integrative Biology, Zhongshan Hospital, Fudan…
- Shanghai Engineering Research Center of Ultra-precision Optical Manufacturing, College of Future Information Technology, Key Laboratory of Micro and Nano Photonic Structures (Ministry of Education), Fudan University, Sh…
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Liu, J., Xiao, B. W., Mai, X., Wang, Y. C., Fei, Y., Wang, Y., & Hou, S. X. (2026). ARRDC4 drives Tau pathology via USP14‐mediated deubiquitination and acts as a novel therapeutic target in Alzheimer's disease. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71926
Vancouver
Liu J, Xiao BW, Mai X, Wang YC, Fei Y, Wang Y, et al. ARRDC4 drives Tau pathology via USP14‐mediated deubiquitination and acts as a novel therapeutic target in Alzheimer's disease. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71926
BibTeX
@article{Liu2026,
author = {Liu, Jiaqi and Xiao, Bing-Wen and Mai, Xiaohan and Wang, Yi-Chun and Fei, Yiyan and Wang, Yang and Hou, Steven X},
title = {ARRDC4 drives Tau pathology via USP14‐mediated deubiquitination and acts as a novel therapeutic target in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71926}
}
EUVIMED